| |
Endpoints 11: Join Us for This Live Streamed Event Celebrating Innovative Science and Entrepreneurship |
|
|
Location: Live Stream – Virtual Date: September 22nd Time: 6:00 pm – 7:30 pm E.T. |
|
|
Which 11 biotech startups stand out from the pack that have launched this year? John Carroll, Founder and Editor of Endpoints News, and Alessandro Maselli, CEO & President, Catalent Pharma Solutions, will co-host the Endpoints 11 award ceremony – Big Dreams Dominate Among Next-Gen Biotech Players, a complimentary live-streamed event taking place in Boston that celebrates innovative science and entrepreneurship.
Catalent is especially pleased to support emerging innovators by being the preferred partner for development and manufacturing, helping to simplify and de-risk programs with integrated solutions, share our deepest development expertise, and have the broadest portfolio of drug delivery technologies and manufacturing platforms across modalities. |
|
|
| |
STAT Event: When the Barrier to a
Breakthrough Drug is You Can’t Make It |
|
|
Location: Virtual – Free of Charge
Date: September 28th Time: 1:00 pm – 2:00 pm E.T. |
|
|
Despite all their promise, newer medicines, especially those based on advanced technologies, have been met with unprecedented challenges in scaling-up manufacturing, quality control and commercial launch. Learn how top developers such as BioNTech and BioMarin have approached different aspects of the manufacturing process to bring new and innovative treatments to patients. Catalent is pleased to be part of this important discussion of the vital role of reliable manufacturing in delivering innovative and breakthrough treatments for patients.
Part 1: BioNTech’s Plans to Bring mRNA to the World
How can mRNA be manufactured in Africa? What are the logistical challenges of new, personalized mRNA cancer vaccines? A look at BioNTech’s plans with Sierk Poetting, Ph.D., chief operating officer, BioNTech
Part 2: BioMarin’s Plans to Make a New Gene Therapy
BioMarin’s hemophilia gene therapy, Roctavian, will present specific challenges when it comes to manufacturing. Learn how the company has been investing for years to solve them with C. Greg Guyer, Ph.D., chief technical officer and executive vice president of global manufacturing and technical operations, BioMarin. |
|
|
| |
Catalent Expands Capabilities
to Accelerate Customer Programs |
|
|
As the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, Catalent continues to invest in the future with a large expansion in Bloomington, IN and recent acquisitions in Oxford, UK, Princeton, NJ and Greenville, NC.
These investments strengthen Catalent’s global capabilities in development, integrated manufacturing, and custom solutions to help customers simplify and accelerate their programs and transform innovation into real treatments for patients. |
|
|
| |
Realize Your Career Purpose & Human Potential.
Join our Growing Team! |
|
|
Catalent invests in the development of their people by creating an inclusive, innovative environment to ignite their future career. We are expanding our capability and growing rapidly across our global sites including but not limited to: Bloomington, Madison, Baltimore, Princeton, Kansas City, Swindon, Gosselies, Oxford. |
|
|
| |
| |
| |
